PDCD1 and neoplasm: Although in recent years, predictive biomarkers based on PD-1/PD-L1 expression, tumor-infiltrating lymphocytes (TILs), and the genetic characteristics of tumor tissue have been reported (12, 13), these markers have yet to be widely validated or used to predict clinical benefits, and thus clinical risk factors still serve as a foundation for treatment choices.